An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

This observational study (no experimental treatment) is following patients in Germany who are receiving nivolumab (an immunotherapy drug) combined with platinum-based chemotherapy before surgery for non-metastatic non-small cell lung cancer, to track real-world outcomes and quality of life. **You may be eligible if...** - You are 18 or older - You have been diagnosed with non-metastatic (not spread to distant organs) non-small cell lung cancer - Your tumor shows PD-L1 expression of at least 1% - Your doctor has already decided (independently of this study) to treat you with nivolumab plus chemotherapy before surgery - You are willing to complete quality-of-life questionnaires in German **You may NOT be eligible if...** - You have another type of cancer currently requiring treatment - You have contraindications to nivolumab based on the drug's approved guidelines Talk to your doctor to see if this trial is right for you.